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Abstract
Longevity is increasing and the population of older adults is growing. The
biology of aging is conducive to cardiovascular disease (CVD), such that
prevalence of coronary artery disease, heart failure, valvular heart disease,
arrhythmia and other disorders are increasing as more adults survive into old
age. Furthermore, CVD in older adults is distinctive, with management issues
predictably complicated by multimorbidity, polypharmacy, frailty and other
complexities of care that increase management risks (e.g., bleeding, falls, and
rehospitalization) and uncertainty of outcomes. In this review, state-of-the-art
advances in heart failure, acute coronary syndromes, transcatheter aortic valve
replacement, atrial fibrillation, amyloidosis, and CVD prevention are discussed.
Conceptual benefits of treatments are considered in relation to the challenges
and ambiguities inherent in their application to older patients.
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Introduction

Heart failure

The unprecedented growth of the elderly population throughout
the world is evolving as a challenge for clinicians, governments,
and health policy guidance. Older adults differ from those typically
studied in clinical trials, efficacy and outcomes of care often remain
ambiguous for older patients, and growing healthcare cost burdens
for older adults are a related concern. In this review, we highlight
some key advances associated with improved outcomes that have
recently occurred in the management of older adults with cardiovascular disease.

Therapeutic options for the management of HF in older adults
include medications, devices, and behavioral interventions. The
PARADIGM-HF trial randomized 8442 patients with symptomatic HF and a left ventricular ejection fraction ≤40% to the ACE
inhibitor enalapril or to the combination of the angiotensin-receptor
blocker valsartan and the neprilysin inhibitor sacubitril9. Compared
to enalapril, valsartan/sacubitril was associated with significant
reductions in cardiovascular death or hospitalization for HF, as well as
all-cause mortality, cardiovascular mortality, HF hospitalizations,
and HF-related symptoms. Patients ≥65 years and those ≥75 years
derived similar benefits from combination therapy, as did younger
patients. Based on these findings, it is anticipated that valsartan/
sacubitril will be rapidly incorporated into the management of older
and younger patients with HF and reduced ejection fraction (HFrEF).

Demographics
The population of older adults is growing rapidly, particularly as
longevity is also increasing. In the United States, the population
aged 65 and over is projected to be 83.7 million by 2050, almost
double the 43.1 million in 20121. The numbers of those who are very
old (≥85 years) is growing the most rapidly. On a global level, the
population ≥85 years is projected to increase 151% between 2005
and 2030, compared to the increase of only 104% in the population
aged ≥65 years and only 21% for the population under 652. Similar
growth of elderly populations is occurring in both developed and
developing countries. Between 2012 and 2030, the percentages of
adults older than 65 years are expected to increase 33.2% in Japan,
27.9% in Germany, and 25.5% in Italy3. In China, the world’s most
populous country of 1.4 billion, the subgroup aged ≥65 years is
expected to increase by 17.2% by 2030 and 26.8% by 2050, or
stated as numbers, 350 million Chinese (a magnitude that is greater
than the total US population) will soon be senior adults3.

Distinctive implications of aging
Geriatric features often transform healthcare challenges and are
important concerns for clinical decision-making. Whereas cardiovascular management standards are fundamentally oriented to specific cardiac diseases, older adults typically present with multiple
disease states occurring concurrently such that presentation and
management of the cardiac issues are inherently more complex4.
In some cases, multimorbid disease states lead to compounding
instabilities (e.g. heart failure [HF] and renal failure). In other
cases, multimorbidities give rise to new disease states (e.g. HF and
preserved ejection fraction [HFpEF] arising from the substrate of
metabolic disease and inflammation)5. Non-cardiac comorbid conditions also underlie much of the morbidity and rehospitalizations
associated with HF, particularly HFpEF6. Geriatric syndromes are
part of multimorbidity; frailty, sarcopenia, cognitive decline, and
other age-related dimensions of health fundamentally compound
multimorbidity management complexities of cardiac conditions7.
These insights highlight the importance of a holistic approach in
relation to HF as well as other cardiovascular diseases (CVDs)
and call attention to the wide range of idiosyncratic capacities,
vulnerabilities, and therapeutic objectives that typically distinguish
one older cardiac patient from another. Similarly, typical cardiac
medications (e.g. angiotensin-converting enzyme [ACE] inhibitors)
must be regarded not only in terms of their evidence-based cardiac benefits but also in respect to the iatrogenesis they more easily
(even predictably) provoke among older adults (e.g. syncope and
falls) in the context of hypotension, balance or vision impairment,
sleep deprivation, alcohol use, and other common conditions in an
older patient population8.

In contrast to HFrEF, the treatment of patients with HFpEF, the
vast majority of whom are elderly, remains problematic. In the
Treatment of Preserved Cardiac Function Heart Failure With an
Aldosterone Antagonist (TOPCAT) trial, spironolactone failed
to reduce the primary outcome of cardiovascular death, aborted
cardiac arrest, or HF hospitalizations10. Spironolactone reduced HF
hospitalizations at the expense of increased rates of hyperkalemia
and elevated serum creatinine. Hence, the role of spironolactone in
the management of HFpEF remains uncertain.
In the realm of devices, the value of implantable cardioverterdefibrillators (ICDs) in patients ≥75 years of age remains
controversial, and selection of older patients for ICDs must be
individualized11. Mechanical circulatory support (MCS) appears to
be associated with improved outcomes in carefully selected older
adults with advanced HF, albeit with increased risk of complications compared to younger patients12. Pre-morbid frailty is a strong
predictor of worse outcomes in older adults receiving MCS13.
In the domain of behavioral interventions, there is a need for novel
approaches that address HF not in isolation, but rather in the context of a complex array of comorbid conditions and heterogeneous
personal preferences regarding goals of care in order to optimize
patient-centered outcomes14. In addition, the management of HF in
long-term care facilities and at the end-of-life now raises special
considerations to maximize quality of life and reduce suffering15,16.

Acute coronary syndrome
Recent developments in antithrombotic therapy as well as better
information on frailty and outcomes have benefitted older adults
with acute coronary syndrome (ACS). A clinical challenge in older
adults presenting with a myocardial infarction (MI) or undergoing
percutaneous coronary intervention (PCI) is the indication for multiple antithrombotic agents (e.g. atrial fibrillation [AF] or valvular
disease). Triple therapy increases the rate of major bleeding, an outcome already common among older adults. Two recent European
registry studies further the understanding of antithrombotic therapy in patients with AF with MI and/or undergoing PCI. Among
older adults requiring oral anticoagulation presenting with MI or
undergoing PCI, clopidogrel added to oral anticoagulant therapy
was as effective as triple therapy (including aspirin) in preventing
MI/coronary death, ischemic stroke, and bleeding17. In another
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study, among patients requiring oral anticoagulation undergoing
PCI (80% ACS, 65% drug-eluting stent and 30% bare metal stent),
use of clopidogrel without aspirin was also associated with less
bleeding and no increase in thrombotic events during follow up18.
A supporting secondary analysis from a large AF clinical trial found
the oral anticoagulant apixaban had similar beneficial effects on
stroke, MI, and major bleeding, with or without aspirin, compared
with warfarin19. Ongoing research is exploring the ability to omit
aspirin in the setting of an effective oral anticoagulant. These new
and safer antithrombotic strategies will be an important advance for
high-risk individuals with coronary artery disease and indications
for oral anticoagulation.
Older adults are at high risk of adverse outcomes following MI, but
a Medicare linkage analysis from the CRUSADE Registry provides
evidence that most mortality occurs early and not in the context of
rehospitalization. Contrary to expectations, rehospitalization rate did
not rise substantially with age, in part due to competing mortality.
Rehospitalizations which did occur were often for non-cardiac
diagnoses, underscoring the multimorbidity also present in the older
population with a coronary event20. The TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute
Coronary Syndromes (TRILOGY ACS) trial, which randomized
9326 patients with MI planned for medical management to prasugrel or clopidogrel, added frailty assessment at baseline for patients
aged ≥65 years21. The modified Fried score classified 23.0% of the
older adults in this trial as pre-frail (1–2 items) and 4.7% as frail
(≥3 items). After adjustment, frailty remained independently associated with the composite of cardiovascular death, MI, or stroke:
pre-frail vs. not-frail, hazard ratio (HR): 1.33; 95% confidence
interval (CI): 1.15–1.54; p<0.001; frail vs. not-frail, HR: 1.52; 95%
CI: 1.18–1.98; p=0.002. Frailty among registry populations is
higher than in clinical trials, so care delivery models should add
early targeted follow up in older adults after MI, particularly for
those with multimorbidity or frailty. Future studies will benefit
from collecting frailty data to allow comparative effectiveness and
outcomes comparisons across older MI or PCI populations.

Transcatheter aortic valve replacement
Transcatheter aortic valve replacement (TAVR) represents an innovative interventional technology that provides a non-surgical alternative for the management of severe aortic stenosis (AS) that has
particular relevance for the elderly and the very elderly populations.
The prevalence of AS in the US is estimated to be greater than
4–5% of those over 75 years of age. Approximately 50% of all US
patients and over 75% of those over 80 years of age having clinical
indications for surgical aortic valve replacement (AVR) are not
being surgically treated due to either the lack of referral by clinicians or patient/family refusal. The use of TAVR has been projected
to make substantial inroads in this underserved population, particularly those who are very elderly or deemed at high surgical risk.
The key randomized clinical trials (RCTs) PARTNER A & B
(utilizing Edwards’ Sapien balloon expandable AVR) along with the
CoreValve (Medtronic’s self-expanding percutaneous AVR) study
of high-risk patients conclusively demonstrated improved longterm patient survival employing TAVR compared to sAVR (standard

surgical AVR) with acceptable stroke and bleeding rates for patients
felt either surgically inoperable or at very high surgical risk. The
median age of TAVR implantation in these study cohorts was
approximately 84 years22,23.
TAVR had been available for clinical use in over 31 countries prior
to United States FDA approval in 2011. To help ensure a rational
diffusion of TAVR’s innovative technology partnerships between
the Food and Drug Administration (FDA), the Center for Medicare
and Medical Services (CMS) along with cardiovascular professional
societies led by the American College of Cardiology (ACC) and
the Society for Thoracic Surgery (STS) collaborated in the creation
of critical Post Approval Studies, CMS Coverage Determination
Criteria, a multi-societal competency document for institutional
and professional utilization of TAVR technology accompanied
by an expert consensus document and clinical practice guidelines
for TAVR clinical use. STS and ACC have created the STS/ACC
transcatheter valve therapy (TVT) Registry where all commercial
TAVR implants are required to be enrolled by hospitals to satisfy
CMS coverage and payment requirements24–27. As of spring 2015,
over 30,000 TAVR patients from approximately 350 institutions
have been entered into the TVT Registry.
The TVT Registry data has been instrumental in assuring quality
of care along with providing the infrastructure for performing Post
Approval Studies, Investigational Device Exemption Studies, and
Post Market Surveillance28,29. The Registry allowed earlier FDA
approval than would be possible through previous RCT mechanisms
for “Valve-in-Valve” TAVR use and also for alternative access use
in high-risk and surgically inoperable patients. The TVT Registry
demonstrated 7.0% 30-day mortality, and 23.7% 1-year mortality
with a stroke rate of 4.1%30.
Of great importance for assessing clinical decision-making for elderly patients with AS, the TVT Registry is collecting both baseline
and longitudinal data on frailty and activity limitation assessments
through 5-meter walk tests and the Kansas City Cardiomyopathy
Questionnaire (KCCQ). In addition, the TVT Registry is creating
a risk-adjusted mortality model that will hopefully soon be transformed into a predictive outcome tool to help clinicians, patients,
and families make informed decisions in the management of elderly
and very elderly patients with AS.

Atrial fibrillation
The median age of patients with AF is 75 years, with a prevalence of about 9% in the elderly31. Stroke stands out as one of the
greatest risks attributable to this arrhythmia. The 2014 American
Heart Association/ACC/Heart Rhythm Society (AHA/ACC/HRS)
guideline32 recommends using the CHA2DS2-VASc (Congestive HF
[CHF], Hypertension, Age ≥75 years, Diabetes, Stroke/Transient
ischemic attack [TIA], Vascular disease, Age 65–74, Sex category
[female]) score to assess stroke risk. The guideline recommends oral
anticoagulant therapy for AF patients with a CHA2DS2-VASc >2
using warfarin or one of the new oral anticoagulants (NOACs)
dabigatran, rivaroxaban, or apixaban. Edoxaban is another NOAC
that was approved for use after the guideline was published, but it
has efficacy that is comparable to those approved earlier.
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As age >75 years leads to a minimum CHA2DS2-VASc score of 2,
many emphasize the value of anticoagulation for most elderly
patients with AF and decry the underuse of such vital therapy.
Nonetheless, this still remains an issue of debate amidst age-related
intricacies of care, i.e. intrinsic bleeding risks are often compounded
by frailty, multimorbidity, polypharmacy, falls, and other management complexities.

the most common in the United States with a particularly high frequency (prevalence of 3.4% to 3.9%) in African-Americans44. The
Thr60Ala mutation (substitution of alanine for threonine at position 60) is also notably common in individuals of Irish descent and
is referred to as the Appalachian mutation. These genetic conditions have an age-dependent penetrance, with males over the age of
60 years being most commonly affected.

There have been several studies to estimate the risk/benefit ratio
of treating elderly AF patients with oral anticoagulation, including
the Birmingham Atrial Fibrillation Treatment of the Aged (BAFTA)
study33, which randomized individuals aged ≥75 years of age to
aspirin or warfarin based on physician discretion. Stroke/systemic
embolism (SE) occurred at a rate of 1.8%/year in warfarin-treated
patients versus 3.8%/year in the aspirin group (HR 0.48; 95%
CI, 0.28–0.80), with no difference in the rates of major hemorrhage
(1.9 vs. 2.2%, respectively). The risk for bleeding with warfarin
therapy in patients >80 years of age has been estimated to range
from 1.63% to 13.1% per year34,35.

Historically, cardiac amyloid was difficult to diagnose because it can
masquerade as other cardiovascular disorders45 and usually required
endomyocardial biopsy. The diagnosis has become easier with the
discovery that bone isotopes have a very high sensitivity and specificity for distinguishing ATTR cardiac amyloid (both mutant
and wild-type) from light chain (AL) cardiac amyloid46 and other
types of cardiomyopathy that mimic amyloid (e.g. hypertrophic
cardiomyopathy). Differentiating TTR from AL cardiac amyloid
has important prognostic, management, counseling, and therapeutic
implications. These nuclear medicine techniques have the potential
to dramatically alter the outcomes of patients with ATTR cardiac
amyloidosis, particularly because new therapeutic options are looming.

The NOACs have generated much excitement in the field of AF
management, as they enable relatively simplified treatment compared to warfarin (e.g. reduced need for blood testing and no dietary
restrictions). NOACs that include both direct thrombin inhibitors
(dabigatran) and factor X inhibitors (rivaroxaban, apixaban, and
edoxaban) are now available as alternatives to warfarin. All have
been shown to be non-inferior to warfarin with respect to stroke and
SE, with comparable rates of bleeding36–39. The mean age of patients
in these studies was approximately 70 years, with about one-third
of the patients being over 75 years.
A recent meta-analysis of the efficacy and harm of the NOACs for
prevention of stroke in AF and secondary prevention of thromboembolism found that the efficacy of each of the NOACs was equal or
superior to warfarin in elderly patients40. Dabigatran was associated
with a higher risk of gastrointestinal bleeding and a lower risk of
intracranial bleeding. A significantly lower risk of major bleeding
compared to warfarin was found for apixaban (odds ratio 0.63, 95%
CI 0.51–0.77) and edoxaban 60 mg (0.81, 0.67–0.98) and 30 mg
(0.46, 0.38–0.57), while rivaroxaban showed similar risks.

Amyloidosis
Cardiac amyloid has traditionally been considered a rare cardiovascular condition. However, emerging data demonstrate that transthyretin cardiac amyloidosis (ATTR), formerly known as senile cardiac
amyloidosis, caused by misfolded monomers or oligomers of the
protein transthyretin (TTR), is a common cause of HFpEF. Indeed
recent autopsy studies in HFpEF subjects (mean age 76 years)
showed 21% had amyloid deposits and the prevalence was greater
in those ≥75 years (32%) vs. <75 years (8%). Furthermore, only
20% of the HFpEF patients with amyloid at autopsy had received a
pre-morbid diagnosis41.
Bone isotopes, commonly used in bone scans, have a high sensitivity and specificity (>90%) for identifying TTR cardiac amyloid due to either wild-type TTR or a mutant allele42,43. While over
20 mutations can cause TTR cardiac amyloidosis, the Val122Ile
mutation (substitution of isoleucine for valine at position 122) is

Emerging therapeutic strategies to treat ATTR amyloid are focused
on small molecules to stabilize the transthyretin tetramer and
agents to silence TTR production. Phase II clinical trial data47 suggest that tafamidis was generally well tolerated and stabilized TTR,
leading to a phase III clinical trial that has completed enrollment.
TTR silencers using either small interfering RNA (siRNA) or oligonucleotides specific for silencing TTR production have shown
remarkable ability to lower TTR to >80% of normal levels in subjects with TTR cardiac amyloidosis. Collectively, such data remind
us that TTR cardiac amyloid is certainly not rare and hopefully not
unmodifiable.

Preventive care
Recent guidelines for cardiovascular prevention importantly
emphasize that older adults are at highest risk for atherosclerotic
cardiovascular events. Paradoxically, however, strategies focused
on cardiovascular prevention are often underutilized in this
subpopulation48. As the elderly also have the greatest burden of
comorbidities, polypharmacy, and potential for medication-related
side effects, the need for comprehensive and collaborative clinician-patient management is imperative49.
Potential overtreatment of hypertension, in addition to inadequate
control, may cause adverse outcomes in the elderly, who are more
likely to have target organ damage. Considerable debate has arisen
from the guideline recommendations made by the panel members
appointed to JNC 8 (Eighth Joint National Committee) that blood
pressure should be reduced to less than 150/90 mm Hg in adults
aged 60 years and older without diabetes or chronic kidney disease50.
In support of the ACC/AHA 2011 Expert Consensus document on
hypertension in the elderly51 that recommended blood pressure be
reduced to less than 140/90 in adults aged 60–79 (and a systolic
pressure of 140–145 if tolerated in adults aged 80 and older) are data
from REGARDS (REasons for Geographic and Racial Differences
in Stroke), which reported that optimal blood pressure for elderly
patients on antihypertensive therapy for the reduction of cardiovascular events and all-cause mortality was less than 140/90 mm Hg52.
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Several recommended caveats for the care of older adults are highlighted by the ACC/AHA 2013 guidelines for the treatment of
blood cholesterol, including the use of moderate-intensity statin
therapy in adults >75 years of age with established atherosclerotic
CVD (ASCVD). The ASCVD pooled cohort risk estimator does
not provide for risk assessment in patients >79 years of age53. When
initiating statin therapy, the risk of transitioning to diabetes should
be discussed, although this risk is small in relation to the potential
benefits of statin medications. Importantly, there is no definitive
evidence that statins lead to cognitive decline. The available
data on the use of proprotein convertase subtilisin/kexin type
9 (PCSK9) inhibitor therapy in those of advanced age is promising,
as low-density lipoprotein (LDL)-C is potently reduced with a side
effect profile similar to that of placebo54.
Lifestyle approaches remain the cornerstone for cardiovascular prevention in the elderly. Among persons aged 55 to 80 (mean age 67)
at increased cardiovascular risk, a Mediterranean diet supplemented
with extra-virgin olive oil or mixed nuts reduced the incidence of
major cardiovascular events by 30%55. Emphasizing a goal of living longer and better, a Mediterranean lifestyle including dietary
pattern, moderate alcohol intake, regular physical activity, and not
smoking was associated with a 60% reduction in all-cause mortality
in elderly Europeans aged 70–9056.

The value of geriatric measures in patient-centered
decision-making for clinical cardiovascular problems
In general, medications, procedures, and other components of cardiovascular care are more likely to entail trade-offs at elderly age.
Polypharmacy, pain, fatigue, confusion, dysgeusia, excessive time
for recovery, and other sequelae may detract from (and sometimes
even supersede) intended therapeutic benefits57,58. Whereas life
prolongation is the overriding goal of therapy in the young, for
many seniors issues of independence, quality of life, and functional
capacity are often more important, and this may determine therapeutic choices that contrast with those of younger populations. This
broader spectrum of clinical objectives and the high susceptibility
to iatrogenesis are driving rationales for a growing emphasis on
principles of shared decision-making between older patients and
their clinicians57,58.
Other age-related issues that commonly affect caregiving of older
cardiac patients include frailty, altered body composition (diminished

lean body mass and increased interstitial fat), and changes in
cognition. Frailty is often assessed as a constellation of phenotypic
changes that relate to a state of increased vulnerability, i.e. slowing,
weakening, weight loss, exhaustion, and reduced activity59. Patients
with three or more of these measures are considered frail and are
generally at increased risk for disease but also for poor tolerance
of therapy. Frailty therefore fundamentally factors into therapeutic
decisions and management strategies. Sarcopenia or reduced lean
body mass is a subpart of frailty and directly detracts from physical capacity and vital resiliency to recover60. Diminished cognition,
particularly executive function, is similarly insidious and detrimental,
and complicating with regard to decision-making and adherence,
and even in respect to the quality of life benefits that are achievable
by therapy61.
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